headquart bedford massachusett
corpor diabet pure play develop
manufactur omnipod insulin pump
omnipod system uniqu place insulin
reservoir bodi thu elimin need
reason report
estim chang analysi sales/earn
maintain e/v invest rate reiter
share open lower due signific impli deceler
annual revenu growth midpoint
corpor guidanc coupl on-going invest
support compani on-going develop hinder oper
margin expans fh opinion
annual revenu growth guidanc appear conserv
result revis revenu estim modestli exce upper
bound corpor guidanc million equival
compani new product pipelin remain on-track could
contribut modest upsid factor guidanc result
fundament like model relat growth opportun
maintain valuation-bas e/v rate must assuag
street growth concern prior move sustain higher
reiter price reiter price target
per share recal price target
corp deriv assign revenu multipl
approxim revis revenu estim
chang estim lower former
million revenu estim million former per
share earn estim per share likewis
moder former revenu earn estim
million per share per share
valuat summari podd share current valu
peer trade revenu assum exce
initi corpor guidanc realiz annual revenu growth
low mid corpor growth would in-lin top
growth compani med tech boast averag growth rate
howev even would still fall materi
averag growth rate fastest grow
med tech concern command averag revenu
multipl accordingli advoc valuat
excess base lower rate growth end market
characterist releg maintain e/v invest
import disclosur analyst certif page report access current disclosur stephen
inc cover compani client may refer
corpor guidanc establish establish revenu guidanc rang million
million pre-cal consensu million specif compani establish omnipod revenu growth
guidanc rang impli revenu growth rang million million
pre-cal consensu million intern omnipod revenu growth impli revenu
million million pre-cal consensu million furthermor compani establish drug
deliveri revenu growth impli revenu million million pre-cal consensu
million furthermor compani establish adjust ebitda margin guidanc mid-teen addit
establish revenu growth guidanc rang impli revenu million
million pre-cal consensu million deriv revenu guidanc compani establish
 omnipod revenu growth guidanc rang impli revenu million
million pre-cal consensu million intern omnipod revenu growth guidanc rang
impli revenu million million pre-cal consensu million lastli compani
establish drug deliveri revenu growth guidanc rang impli revenu
million million pre-cal consensu million
oper review podd revenu million pre-cal consensu million increas
year year busi segment domest omnipod revenu million pre-cal consensu
million increas year year intern omnipod revenu increas million pre-
call consensu million compani report drug deliveri revenu million pre-cal consensu
million repres year year growth report quarterli gross margin pre-cal
consensu repres declin driven primarili compani domest manufactur ramp
furthermor total oper expens million increas year year sale market expens
increas million research develop expens increas million gener
administr expens increas million result report oper incom million
earn per share pre-cal consensu per share
busi initi on-track begun compani omnipod horizon pivot trial consist
patient age year age year old remain on-track potenti commerci
addit expand partnership o/v rate abbott rate integr
compani cgm offer omnipod horizon system addit expand market access includ
pharmaci benefit channel furthermor compani instal second manufactur line
anticip product mid-year also remain on-track instal third line late ahead launch
horizon recal line design provid compani current china oper capac
less headcount line requir approxim month scale full capac
balanc sheet review exit oper period million cash cash equival short-
term invest million debt net debt posit per dilut share
period
dollar thousand except per share data
fiscal period
fiscal period
fiscal period
product revenu
research develop
gener administr
sale market
research develop
gener administr
sale market
research develop
forma ep exclud non-recur expens stock-bas compens quarter neg earn basic share outstand use calcul ep
compani report stephen inc estim
analyst primarili respons prepar content report certifi view express report
accur reflect analyst person view subject compani secur ii part analyst compens
directli indirectli relat specif recommend view express analyst report
